Axsome Therapeutics Inc. (AXSM) Receives Average Rating of “Strong Buy” from Brokerages
Axsome Therapeutics Inc. (NASDAQ:AXSM) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1 year consensus target price of $23.33 for the company, according to Zacks. Zacks has also assigned Axsome Therapeutics an industry rank of 109 out of 265 based on the ratings given to its competitors.
Several brokerages have weighed in on AXSM. Brean Capital set a $29.00 target price on Axsome Therapeutics and gave the stock a “buy” rating in a report on Sunday, August 21st. Zacks Investment Research cut Axsome Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. Finally, Cantor Fitzgerald set a $13.00 target price on Axsome Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 10th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/axsome-therapeutics-inc-axsm-receives-average-rating-of-strong-buy-from-brokerages.html
Axsome Therapeutics (NASDAQ:AXSM) traded up 0.24% on Wednesday, hitting $8.19. 3,576 shares of the company traded hands. The firm’s market capitalization is $156.83 million. The firm’s 50 day moving average price is $7.64 and its 200 day moving average price is $8.39. Axsome Therapeutics has a 1-year low of $5.37 and a 1-year high of $15.74.
Large investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. bought a new stake in shares of Axsome Therapeutics during the second quarter worth $134,000. Lombard Odier Asset Management USA Corp boosted its stake in shares of Axsome Therapeutics by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 341,790 shares of the company’s stock worth $2,577,000 after buying an additional 9,400 shares during the period. Mariner Wealth Advisors LLC bought a new stake in shares of Axsome Therapeutics during the second quarter worth $313,000. State Street Corp bought a new stake in shares of Axsome Therapeutics during the second quarter worth $856,000. Finally, Teachers Advisors Inc. bought a new stake in shares of Axsome Therapeutics during the second quarter worth $128,000. Hedge funds and other institutional investors own 30.30% of the company’s stock.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.